Fluids, Electrolyte's Imbalances, ESA's Renal Pharmacology

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

34 Terms

1
New cards

Hyperkalemia — ECG Changes

Produces peaked T waves (best seen in precordial leads like V2), a shortened QT interval, and small or indiscernible P waves (seen in leads V5–V6); severe levels (> 6.5 mEq/L) can progress to ventricular fibrillation

2
New cards

Calcium Chloride / Calcium Gluconate in Hyperkalemic ECG Changes

Used in severe hyperkalemia (> 6.5 mEq/L) to stabilize the cardiac resting membrane potential and prevent ventricular fibrillation; does not lower serum potassium levels

3
New cards

Hypokalemia — Cardiac & ECG Considerations

Causes cardiac arrhythmias and ECG abnormalities requiring continuous cardiac monitoring during IV potassium replacement when serum K+ < 3.0 mEq/L or marked symptoms are present. (Classic ECG findings: flattened or inverted T waves, ST-segment depression, and prominent U waves.)

4
New cards

Hypocalcemia & Hypercalcemia — Classic ECG Changes

(Supplement to lecture notes) Hypocalcemia prolongs the QT interval (via prolonged ST segment), whereas hypercalcemia shortens the QT interval

5
New cards

Normal Serum Calcium & Hormonal Regulation

Reference range is 2.1–2.6 mmol/L; regulated by PTH (raises serum Ca2+ via bone resorption, renal reabsorption, and vitamin D activation while increasing urinary phosphate excretion), calcitriol (increases GI absorption of Ca2+ and phosphate), and calcitonin (lowers serum Ca2+ by inhibiting bone resorption)

6
New cards

Calcium Gluconate 10% Injection (Acute Hypocalcemia)

Administered via slow IV infusion to rapidly correct acute symptomatic hypocalcemia; warm vial if crystallization occurs and discard unused portion

7
New cards

Calcitriol (Rocaltrol®)

Most active form of vitamin D 3, 100 times more potent than vitamin D3; treats chronic hypocalcemia by directly stimulating intestinal Ca2 absorption without requiring renal 1alpha-hydroxylase activation

8
New cards

Paricalcitol (Zemplar®)

Synthetic vitamin D2 analog used in chronic hypocalcemia and CKD mineral bone disorder to increase calcium absorption and suppress PTH

9
New cards

Ergocalciferol & Cholecalciferol

Oral vitamin D2</strong></span>(ergocalciferol)and<strong>vitamin</strong><span><strong>D3</strong></span> (ergocalciferol) and <strong>vitamin </strong><span><strong>D3 (cholecalciferol) supplements used alongside oral calcium (and magnesium if deficient) to manage chronic hypocalcemia

10
New cards

Hypercalcemia Treatment Thresholds

Asymptomatic levels < 12\ require no treatment; moderate levels (12–14mg/dL} require hydration if asymptomatic or targeted therapy if symptomatic; levels > 14\require aggressive treatment regardless of symptoms

11
New cards

Hypercalcemic Crisis Regimen

First-line acute management consists of 0.9% normal saline rehydration followed by furosemide (Lasix®) loop diuresis (promotes urinary Ca^2+ excretion), calcitonin (rapidly inhibits bone resorption), and bisphosphonates

12
New cards

Bisphosphonates (Hypercalcemia)

Accumulate in bone and powerfully inhibit osteoclast-mediated bone resorption; key for malignancy-associated or severe hypercalcemia.

13
New cards

Cinacalcet (Sensipar®)

Oral calcimimetic that binds the 7-transmembrane domain of the calcium-sensing receptor (CaSR) to increase receptor sensitivity and suppress PTH secretion; approved for secondary hyperparathyroidism (HPT) in CKD on dialysis, parathyroid carcinoma, and tertiary HPT; acts as a strong CYP2D6 inhibitor and CYP3A4 substrate.

14
New cards

Etelcalcetide (Parsabiv®)

IV synthetic peptide calcimimetic that allosterically activates the extracellular domain of the CaSR to lower PTH in adult CKD patients with secondary HPT on hemodialysis; adverse effects include hypocalcemia, muscle spasms, GI upset, headache, and paresthesias (numbness/tingling in extremities or perioral area)

15
New cards

Hemodialysis / Peritoneal Dialysis (Hypercalcemia)

Reserved for severe, refractory hypercalcemia, particularly in patients with concurrent renal failure

16
New cards

Normal Serum Phosphorus & Severity Thresholds

Reference range is 2.5–4.5mg/dL; moderate hypophosphatemia is 1.0–2.4mg/dL and severe hypophosphatemia is < 1.0mg/dL

17
New cards

Oral Phosphate Replacements (Hypophosphatemia)

Preferred first-line therapy (limited by diarrhea; use caution in CKD

18
New cards

IV Phosphate Replacements (Severe Hypophosphatemia)

Sodium Phosphate IV (93 mg P and 4.0 mEq Na/mL) and Potassium Phosphate IV (93mgP and 4.4mEqK/mL for severe depletion (< 1.0\ mg/dL or when oral intake is not possible.

19
New cards

Phosphate Binders — Mechanism of Action (Hyperphosphatemia

Bind dietary phosphate in the GI lumen to form insoluble complexes excreted in the feces, preventing intestinal absorption in advanced CKD.

20
New cards

uminum Hydroxide (Phosphate Binder)

Calcium-free liquid binder; effective and low cost, but limited to 4 weeks of use due to risks of osteomalacia, anemia, and CNS toxicity.

21
New cards

Calcium Acetate (PhosLo®) & Calcium Carbonate (Phosphate Binders):

ow-cost, effective binders containing 169 mg (PhosLo® $667 mg) and 400 mg (calcium carbonate 1 g) elemental calcium; limited by high pill burden and risks of hypercalcemia, vascular calcification, and adynamic bone disease (ADB).

22
New cards

Sevelamer Carbonate (Renvela®)

Calcium-free polymeric phosphate binder (800 mg); also lowers LDL cholesterol, but carries a high pill burden, swallowing difficulties, and interferes with fat-soluble vitamin D and K absorption.

23
New cards

Lanthanum Carbonate (Fosrenol®)

Calcium-free phosphate binder (750 mg) with a low pill burden; primary adverse effects are gastrointestinal.

24
New cards

Sucroferric Oxyhydroxide (Velphoro®)

Calcium-free, iron-based phosphate binder (500 mg) with a low pill burden and potential to increase transferrin, iron, and hemoglobin; drawbacks include high cost and potential long-term iron accumulation.

25
New cards

Tenapanor (Alternative Hyperphosphatemia Agent)

Small-molecule inhibitor of intestinal NHE3 (Na+/H exchanger isoform 3) that reduces passive paracellular phosphate absorption.

26
New cards

Nicotinamide & ASP3325 (Alternative Hyperphosphatemia Agents)

Inhibit active sodium-dependent transcellular NaPi-IIb cotransporters in the enterocyte to reduce intestinal phosphate uptake.

27
New cards

Pathophysiology of Anemia in CKD

Renal injury causes erythropoietin-producing peritubular interstitial cells (EPCs) to transdifferentiate into collagen-producing myofibroblasts, decreasing endogenous EPO production; concurrent iron deficiency (25–70% prevalence) further impairs hemoglobin synthesis.

28
New cards

Oral Iron Supplements (CKD Anemia):

nclude ferrous sulfate 325 mg tab = 65mg elemental iron), ferrous gluconate (Fergon®) (324 mg tab = 37.5 mg elemental iron), and ferric citrate (Auryxia®) (also functions as a phosphate binder).

29
New cards

ntravenous (IV) Iron Supplements (CKD Anemia)

referred in hemodialysis or patients intolerant/unresponsive to oral iron; includes iron sucrose (Venofer®) (100 mg/5 mL), ferumoxytol (Feraheme®) (510 mg/17 mL), ferric carboxymaltose (Injectafer®), iron dextran (Infed®), and ferric gluconate.

30
New cards

Erythropoietin-Stimulating Agents (ESAs) — Mechanism

Recombinant human EPO analogs that bind EPO receptors (EPOR) on bone marrow erythroid progenitors (CFU-E, proerythroblasts, basophilic erythroblasts) to stimulate red blood cell proliferation and raise hemoglobin.

31
New cards

Epoetin Alfa (Epogen®, Procrit®, Eprex®; Biosimilar: Retacrit™)

First-generation recombinant human EPO used in CKD and chemotherapy-induced anemia; shorter half-life requiring 3-times-weekly administration

32
New cards

Darbepoetin Alfa (Aranesp®) & Methoxy PEG-Epoetin Beta (Mircera®)

Second-generation (darbepoetin alfa) and third-generation pegylated (Mircera®) ESAs engineered with longer half-lives for less frequent dosing than epoetin alfa.

33
New cards

Daprodustat (Jesduvroq®) — Mechanism & Indication:

Oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor; prevents PHD-mediated hydroxylation and VHL proteasomal degradation of HIF-alpha, increasing nuclear HIF transcription of endogenous EPO and erythropoiesis; approved for CKD anemia in adults on dialysis for > 4 months (not approved for non-dialysis patients)

34
New cards

Daprodustat (Jesduvroq®) — Administration & Adverse Effects

Swallow tablets whole (do not cut, crush, or chew); noninferior to darbepoetin alfa for hemoglobin maintenance and cardiovascular safety; adverse effects include hypertension, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions.